A Historic Moment for Gene Editing
In November 2023, the UK's MHRA became the first regulatory body to approve Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The FDA followed in December 2023, and the EMA granted approval in early 2024. This marked the first time a CRISPR-based therapy was approved for clinical use anywhere in the world.
Casgevy treats two related blood disorders: sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Both conditions result from mutations in the genes that produce hemoglobin — the protein in red blood cells that carries oxygen throughout the body.
The Science Behind Casgevy
Casgevy doesn't fix the mutated hemoglobin gene directly. Instead, it takes an elegant detour through fetal hemoglobin.
During fetal development, humans produce a different form of hemoglobin (HbF) that binds oxygen more tightly than adult hemoglobin. After birth, a gene called BCL11A acts as a switch, turning off fetal hemoglobin production and turning on adult hemoglobin. In patients with SCD or TDT, the adult hemoglobin is defective — but their fetal hemoglobin genes are perfectly fine.
Casgevy uses CRISPR-Cas9 to edit the BCL11A gene in the patient's own bone marrow stem cells. By disrupting this molecular switch, the cells resume producing fetal hemoglobin, which compensates for the defective adult hemoglobin.
The Treatment Process
- Stem cell collection: The patient's bone marrow stem cells (CD34+ hematopoietic stem cells) are collected via apheresis
- Ex vivo editing: In the lab, CRISPR-Cas9 is used to edit the BCL11A enhancer in these cells
- Myeloablative conditioning: The patient undergoes chemotherapy to destroy their existing bone marrow (the most challenging part of the treatment)
- Infusion: The edited stem cells are infused back into the patient
- Engraftment: Over weeks to months, the edited cells engraft and begin producing fetal hemoglobin
Clinical Trial Results
The clinical data supporting Casgevy's approval was compelling:
For sickle cell disease (CLIMB-SCD-121):
- 29 of 31 evaluable patients (93.5%) were free of vaso-occlusive crises (VOCs) for at least 12 consecutive months
- Fetal hemoglobin levels increased to 20-45% of total hemoglobin (normal threshold for therapeutic benefit is ~20%)
For beta-thalassemia (CLIMB-THAL-111):
- 39 of 42 evaluable patients (92.9%) achieved transfusion independence
- Patients who previously required regular blood transfusions no longer needed them
Challenges and Limitations
Despite its success, Casgevy faces significant challenges:
- Cost: Listed at $2.2 million per patient in the US, making it one of the most expensive therapies ever approved
- Accessibility: Requires specialized treatment centers, months of treatment time, and intensive monitoring
- Myeloablative conditioning: The chemotherapy required before cell infusion carries serious risks, including infertility and secondary cancers
- Scalability: Each treatment is individualized (autologous), making mass production impossible
What This Means for the Future
Casgevy's approval validates the entire field of CRISPR therapeutics. It proves that gene editing can be safely and effectively used to treat human disease. Several next-generation approaches are already in development that could address Casgevy's limitations:
- In vivo editing: Editing genes directly inside the body, eliminating the need for cell extraction and chemotherapy
- Allogeneic therapies: Using donor cells instead of the patient's own, enabling off-the-shelf treatments
- Base and prime editing: More precise editing tools that don't require double-strand breaks
The era of CRISPR medicine has officially begun.
